Area of research
Immunology · Oncology
Research interest
Research interests include Immunotherapy and Immune Responses, Cancer Immunotherapy and Biomarkers, Cancer Genomics and Diagnostics, and Immune cells in cancer.
Abstract 6821: The temporal dynamics and molecular impact of clonal hematopoiesis in non-small cell lung cancer
Abstract 6793: Clinico-genomic characteristics of multiple primary cancers in TRACERx
Ultrasensitive ctDNA detection for preoperative disease stratification in early-stage lung adenocarcinoma
Clonal driver neoantigen loss under EGFR TKI and immune selection pressures
Prospective validation of ORACLE, a clonal expression biomarker associated with survival of patients with lung adenocarcinoma
Somatic evolution following cancer treatment in normal tissue
152P Association of genetic intra-tumour heterogeneity with outcome in TRACERx
Table S1 from Spatial Positioning of Immune Hotspots Reflects the Interplay between B and T Cells in Lung Squamous Cell Carcinoma
Table S2 from Spatial Positioning of Immune Hotspots Reflects the Interplay between B and T Cells in Lung Squamous Cell Carcinoma
Data from Spatial Positioning of Immune Hotspots Reflects the Interplay between B and T Cells in Lung Squamous Cell Carcinoma
Supplementary Data from Spatial Positioning of Immune Hotspots Reflects the Interplay between B and T Cells in Lung Squamous Cell Carcinoma
Spatial Architecture of Myeloid and T Cells Orchestrates Immune Evasion and Clinical Outcome in Lung Cancer.
Representation of genomic intratumor heterogeneity in multi-region non-small cell lung cancer patient-derived xenograft models
Supplementary Figures 1-22 from Spatial Architecture of Myeloid and T Cells Orchestrates Immune Evasion and Clinical Outcome in Lung Cancer
Abstract PR011: Comprehensive longitudinal tracking of lung cancer evolutionary clonal dynamics during therapy using circulating tumour DNA
LBA9 Clinical insights from ultra-sensitive tumour-informed ctDNA tracking across the TRACERx cohort
Figure 6 from Spatial Architecture of Myeloid and T Cells Orchestrates Immune Evasion and Clinical Outcome in Lung Cancer
Supplementary Figures 1-22 from Spatial Architecture of Myeloid and T Cells Orchestrates Immune Evasion and Clinical Outcome in Lung Cancer
Figure 1 from Spatial Architecture of Myeloid and T Cells Orchestrates Immune Evasion and Clinical Outcome in Lung Cancer
Figure 2 from Spatial Architecture of Myeloid and T Cells Orchestrates Immune Evasion and Clinical Outcome in Lung Cancer
Table S1 from Spatial positioning of immune hotspots reflects the interplay between B and T cells in lung squamous cell carcinoma
Figure 3 from Spatial Architecture of Myeloid and T Cells Orchestrates Immune Evasion and Clinical Outcome in Lung Cancer
Table S2 from Spatial positioning of immune hotspots reflects the interplay between B and T cells in lung squamous cell carcinoma
Supplementary Tables 1-5 from Spatial Architecture of Myeloid and T Cells Orchestrates Immune Evasion and Clinical Outcome in Lung Cancer
Table S1 from Spatial positioning of immune hotspots reflects the interplay between B and T cells in lung squamous cell carcinoma
Data from Spatial Architecture of Myeloid and T Cells Orchestrates Immune Evasion and Clinical Outcome in Lung Cancer
Supplementary Tables 1-5 from Spatial Architecture of Myeloid and T Cells Orchestrates Immune Evasion and Clinical Outcome in Lung Cancer
Figure 4 from Spatial Architecture of Myeloid and T Cells Orchestrates Immune Evasion and Clinical Outcome in Lung Cancer
TRACERx Consortium Members from Spatial Architecture of Myeloid and T Cells Orchestrates Immune Evasion and Clinical Outcome in Lung Cancer
Table S2 from Spatial positioning of immune hotspots reflects the interplay between B and T cells in lung squamous cell carcinoma